Your session is about to expire
← Back to Search
Dendritic Cell Vaccine for Glioblastoma
Study Summary
This trial is testing a new vaccine for people with glioblastoma. The goal is to see if it is safe and if it helps people live longer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You must be able to follow the bi-weekly schedule for receiving DC vaccine injections.
- Group 1: Dendritic cell vaccine dose escalation one
- Group 2: Dendritic cell vaccine dose escalation two
- Group 3: Dendritic cell vaccine: Starting dose
- Group 4: Dendritic cell vaccine dose de-escalation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this an experimental or untested trial?
"Currently, there are 3 ongoing TH-1 Dendritic Cell Immunotherapy trials in 74 cities and 5 countries. This therapeutic area was first explored 14 years ago when Northwest Biotherapeutics launched a Phase 3 drug approval study involving 348 patients. Since then, an additional 4 studies have been concluded."
Is enrollment for this experiment still open?
"Affirmative, this clinical trial is actively recruiting according to information provided on the clinicaltrials.gov website. The research began recruitment on October 11th 2021 and was last amended June 27th 2022, aiming to enrol 24 participants from 2 medical centres."
Has TH-1 Dendritic Cell Immunotherapy been studied previously?
"Presently, 3 clinical trials are examining the efficacy of TH-1 Dendritic Cell Immunotherapy one of which has reached Phase 3. Primarily situated in Camden, New jersey, 91 centres across the country have launched studies on this form of treatment."
Could you please explain the potential risks associated with TH-1 Dendritic Cell Immunotherapy?
"The safety of TH-1 Dendritic Cell Immunotherapy is estimated to be a 1 due to the limited evidence on its efficacy and safety, as this is still an early phase trial."
To what extent is this medical study examining a population of participants?
"Affirmative. Clinicaltrials.gov indicates that this study was listed on October 11th 2021 and has been actively recruiting since then. The 24 participants required are to be drawn from two distinct medical sites."
Share this study with friends
Copy Link
Messenger